Cognition Therapeutics (CGTX) Assets Average (2021 - 2026)

Cognition Therapeutics (CGTX) has 6 years of Assets Average data on file, last reported at $42.3 million in Q1 2026.

• Quarterly Assets Average rose 57.31% year-over-year to $42.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.3 million (up 57.31% YoY) and the FY2025 annual result came in at $39.3 million, up 20.23% from the prior year.
• Assets Average eased to $42.3 million in Q1 2026 per CGTX's latest filing, from $45.9 million in the prior quarter.
• Across five years, Assets Average topped out at $58.9 million in Q1 2022 and bottomed at $21.6 million in Q2 2025.
• The 5-year median for Assets Average is $41.4 million (2023), against an average of $40.7 million.
• Peak annual rise in Assets Average reached 58.76% in 2025, while the deepest fall reached 41.11% in 2025.
• Tracing CGTX's Assets Average over 5 years: stood at $52.0 million in 2022, then fell by 28.9% to $37.0 million in 2023, then slipped by 21.81% to $28.9 million in 2024, then jumped by 58.76% to $45.9 million in 2025, then decreased by 7.9% to $42.3 million in 2026.
• Per Business Quant, the three latest CGTX Assets Average figures stand at $42.3 million (Q1 2026), $45.9 million (Q4 2025), and $31.5 million (Q3 2025).

Peer Comparison